National Pharmaceutical Industries Co.

What National Pharmaceutical Industries Co. does

National Pharmaceutical Industries Co. (SAOC) (NPI) is the first pharmaceutical manufacturer in the Sultanate of Oman, founded in 1999 under the vision of Oman's late Sultan Qaboos and inaugurated in 2001 by His Majesty Haitham bin Tariq Al Said, with the Ministry of Health as the founding sponsor. The company manufactures and markets branded generic oral pharmaceutical products — tablets, capsules, dry powders for reconstitution, sachets, and liquids — across eleven therapeutic categories including cardiovascular, antidiabetic, anti-infective, central nervous system, gastrointestinal, NSAIDs, anti-allergic, and analgesic/antipyretic products, with a branded portfolio of approximately 60+ SKUs (e.g., Torvast, Starval, Dioclav, Omformin). Its manufacturing footprint spans NPI Pharma and NPI Beta in Rusayl, Oman (combined tablet capacity above 1.8 billion per annum plus capsule, dry powder, and liquid lines), the Elixir UAE secondary packaging and batch release facility at Dubai Science Park, and the Elixir Pharma KSA OSD facility under construction at King Abdullah Economic City, Jeddah (planned capacity of 1.0 billion+ tablets and 300 million capsules annually). The company is USFDA accredited, EUGMP certified (2018), and ISO 9001:2015 certified (2019), with EUGMP enabling registrations across 30 European Union countries alongside approvals in GCC, MENA, Africa, and CIS jurisdictions.

NPI operates a vertically integrated model spanning R&D (Elixir Research & Development, a CGLP-compliant centre focused on non-infringing processes, complex formulations, and novel drug delivery systems), regulatory services (Elixir Consulting, providing dossier development, eCTD formatting, GMP inspection support, and pharmacovigilance), contract manufacturing, and direct sales and marketing. Its go-to-market relies on a direct pharmaceutical field sales force with therapy-area-specialized teams (cardiac, antidiabetic, antibiotic, psychiatric) covering 14 front-line countries — Oman, KSA, UAE, Bahrain, Qatar, Kuwait, Iraq, Jordan, Yemen, Libya, Kenya, Somalia, Tanzania, and Malawi — augmented by a distributor and wholesaler network and a hospital and polyclinic channel. The customer base is anchored by the Omani Ministry of Health and Ministry of Defense (the company states it derives major strength from offering best price benefits to these ministries), supplemented by private hospitals, polyclinics, and pharmacy distributors across its geographies. Pricing is not publicly disclosed and is negotiated bilaterally in government tenders.

Revenue is generated primarily through one-time branded generic product sales across multiple therapy areas and, secondarily, through professional services revenue from contract manufacturing and regulatory consulting. Major shareholders include Oman Investment Fund Holding Co and Suhail Bahwan Group, and the board is chaired by Mr. Rashid Saleem Al Aghbari with Ms. Amal Suhail Salim Bahwan Al Mukhaini as Vice Chairman. The company is privately held as a closed joint stock company (SAOC) under Omani law. The company has stated intent to expand into South East Asia, additional African markets, and CIS/European countries beyond the current footprint.

Name

National Pharmaceutical Industries Co.

Legal name

National Pharmaceutical Industries Co. (SAOC)

Website

https://npioman.om

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

NPI is the first pharmaceutical manufacturer in Oman, producing branded generic oral pharmaceuticals (tablets, capsules, dry powders, sachets, liquids) across eleven therapeutic categories. It serves government health ministries, hospitals, and distributors across 14 front-line countries and is registered in 30+ EU countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic pharmaceutical manufacturing
• Branded generic medicines
• Oral solid dosage forms
• Pharmaceutical contract manufacturing
• Regulatory consulting services

Headquarters

HQ city

Rusayl

HQ country

Oman

HQ region

Middle East

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Branded Generic Pharmaceuticals: Manufacturing and sales of branded generic pharmaceuticals across multiple therapy areas including cardiovascular, antidiabetic, anti-infective, CNS, and gastrointestinal. Products sold in GCC, Africa, Europe, and CIS countries.
2. Contract Manufacturing: Third party manufacturing services and contract manufacturing offerings through Elixir Consulting.
3. Regulatory Services: Comprehensive regulatory services including dossier development, submission management, GMP inspection support, and pharmacovigilance support through Elixir Consulting.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

National Pharmaceutical Industries Co. (NPI) manufactures and sells branded generic oral pharmaceutical products — tablets, capsules, dry powders for reconstitution, sachets, and liquids — across 11 therapeutic categories including cardiovascular, antidiabetic, anti-infective, central nervous system, gastrointestinal, NSAID, analgesic, and anti-allergic medicines. The company also offers third-party contract manufacturing and regulatory consulting services through its Elixir Consulting subsidiary, including dossier development, eCTD formatting, product registration, GMP inspection support, and pharmacovigilance.

Product overview

NPI operates as a diversified pharmaceutical company with manufacturing operations across Oman, Saudi Arabia, and UAE. The company produces branded generic medicines across 11 therapeutic categories including Lipid Lowering (Torvast, Viscor, Rostatin), Cardiovascular (Starval, Ceruvin, Losart, Amlopin, Omace, Betaten, Omapril, Irbesar, Olsar, Aspilo), Anti-Allergic (Lohist, Omcet, Coldrin, Telfadin, Omvil, Stopkof), Anti-Bacterials (Dioclav, Cefrax, Levoflox, Spectromax, Omacip, Klox, Omaceph, Omacillin, Omathrocin, Macromax, Omadine, Moxiflox), Niche & Mass (Flucazol, Aladin, Hedralix, Alendromax, ORS, Fluvir, Calcy), NSAIDs (Diclopid, Omatan, Omafen, Oxicam, Narox), Gastrointestinal (Omapro, Motilone, Hycom, Omacid, Rancer, Ondan), Anti-Diabetic (Glipom, Sucrovance, Glimer, Omformin), Anti-Depressant/CNS (Citom, Freeton, Olanex, Mirtaz), and Analgesic Antipyretic (Omol). The company also provides manufacturing services through facilities including NPI Pharma (EU GMP accredited), NPI Beta, Elixir Pharma (KSA under construction), and Elixir UAE, plus R&D services through Elixir Research & Development, regulatory consulting through Elixir Consulting, and sales/marketing through NPI/Elixir Sales & Marketing.

Differentiator

Problem solved

Functional benefit

Brands

• NPI Pharma: Primary manufacturing facility producing oral pharmaceutical products including tablets, sachets, dry powder, liquids, and capsules
• NPI Beta
• Elixir UAE
• Elixir Pharma (KSA)
• Elixir Consulting
• Elixir Sales & Marketing

Products and services

• Lipid Lowering Branded Generics Branded generic lipid-lowering medicines including Torvast (Atorvastatin 10/20/40mg tablets), Viscor (Simvastatin 10/20/40mg tablets), and Rostatin (Rosuvastatin 10/20/40mg tablets), sold to government health systems, hospitals, polyclinics, and distributors in GCC, Africa, and other registered markets.
• Cardiovascular Branded Generics Branded generic cardiovascular medicines including Starval (Valsartan and Valsartan HCT), Ceruvin (Clopidogrel 75mg), Losart (Losartan 50/100mg), Amlopin (Amlodipine 5mg), Omace (Lisinopril 5/10/20mg), Betaten (Atenolol 25/50/100mg), Omapril (Captopril 12.5/25/50mg), Irbesar (Irbesartan 150/300mg), Olsar (Olmesartan 10/20/40mg), and Aspilo (Aspirin 81mg), sold to cardiology prescribers, hospitals, and government healthcare buyers.
• Anti-Allergic Branded Generics Branded generic anti-allergic medicines including Lohist (Loratadine and pseudoephedrine syrups/tablets), Omcet (Cetirizine drops/syrup/10mg tablets), Coldrin (Triprolidine and pseudoephedrine syrups), Telfadin (Fexofenadine 120/180mg tablets), Omvil (Chloropheniramine syrup/4mg tablets), Stopkof (Diphenhydramine and ammonium chloride syrups), and Omcet-L (Levocetirizine 5mg tablets), sold to general practitioners, hospitals, and pharmacy distributors.
• Anti-Bacterial Branded Generics Branded generic anti-bacterial medicines including Dioclav (Amoxicillin and clavulanate), Cefrax (Cefixime 200/400mg), Levoflox (Levofloxacin 500mg), Spectromax (Clarithromycin 250/500mg), Omacip (Ciprofloxacin 250/500mg), Klox (Cloxacillin), Omaceph (Cephalexin), Omacillin (Amoxicillin), Omathrocin (Erythromycin), Macromax (Azithromycin), Omadine (Cephradine), and Moxiflox (Moxifloxacin 400mg), sold to infectious disease prescribers, hospitals, polyclinics, and government health systems.
• Niche and Mass Branded Generics Branded generic niche and mass-market medicines including Flucazol (Fluconazole 50/150mg), Aladin (Sildenafil 25/50/100mg), Hedralix (Dried ivy leaf extract syrup), Alendromax (Alendronic acid 70mg), Alka UR (Urinary alkalinizer sachets), ORS (Oral rehydration salt sachets), Fluvir (Oseltamivir 75mg), Calcy (Calcium carbonate and vitamin D3), Terbisil (Terbinafine 250mg), Tadafil (Tadalafil 20mg), and Monty (Montelukast 10mg), sold to urology, orthopedics, and general practice channels.
• NSAID Branded Generics Branded generic NSAID medicines including Diclopid (Diclofenac potassium 50mg and diclofenac sodium 75mg injection), Omatan (Mefenamic acid 500mg), Omafen (Ibuprofen 100mg/5ml suspension and 400mg tablets), Oxicam (Meloxicam 7.5/15mg), and Narox (Naproxen 250/500mg), sold to orthopedic, rheumatology, and general practice prescribers.
• Gastrointestinal Branded Generics Branded generic gastrointestinal medicines including Omapro (Omeprazole 20mg), Motilone (Omeprazole 10mg), Hycom (Hyoscine N-butyl bromide 10mg), Omacid (Aluminium hydroxide and magnesium hydroxide), Rancer (Ranitidine 150/300mg), and Ondan (Ondansetron 4/8mg), sold to gastroenterology prescribers, hospitals, and pharmacy distributors.
• Anti-Diabetic Branded Generics Branded generic anti-diabetic medicines including Glipom (Glipizide 5mg), Sucrovance (Metformin 500mg and glibenclamide 5mg), Glimer (Glimiperide 1/2/3/4mg), and Omformin (Metformin HCl 100/500/850mg), sold to endocrinology and primary care prescribers, hospitals, and government health systems.
• Anti-Depressant Branded Generics Branded generic anti-depressant medicines including Citom (Citalopram 20mg), Freeton (Buspirone HCl 5/10mg), and Olanex (Olanzapine 5/10mg), sold to psychiatry prescribers, mental health hospitals, and government health systems.
• CNS Branded Generics Branded generic central nervous system medicines including Mirtaz (Mirtazapine 15/30mg), sold to psychiatry and neurology prescribers, mental health institutions, and government health systems.
• Analgesic Antipyretic Branded Generics Branded generic analgesic and antipyretic medicines under the Omol brand (Paracetamol 500mg tablets, extra tablets with caffeine, cold and flu tablets, syrup, and drops), sold to general practice, hospitals, polyclinics, pharmacy distributors, and government health systems.
• NPI Pharma Manufacturing Facility Primary manufacturing facility in Rusayl Industrial Estate, Muscat, Oman, producing tablets (over 1.5 billion per annum), sachets (150M per annum), dry powder (4M bottles per annum), liquids (30M bottles per annum), and capsules (150M per annum). EU GMP accredited, used for both NPI's own branded generics and contract manufacturing for third parties.
• NPI Beta Manufacturing Facility Secondary manufacturing facility in Muscat, Oman producing tablets (over 300 million per annum), dry powder (6 million bottles per annum), and capsules (over 750 million per annum), supplementing capacity of NPI Pharma for oral solid dosage production.
• Elixir UAE Secondary Packaging Facility Secondary packaging and batch release site located at Dubai Science Park, Dubai, UAE. Also houses sales and marketing operations, enabling localized batch release and distribution for the UAE and broader Gulf markets.
• Elixir Pharmaceuticals LLC (KSA) Manufacturing Facility State-of-the-art oral solid dosage (OSD) formulation facility under construction at King Abdullah Economic City, Jeddah, Saudi Arabia. Planned capacity: over 1.0 billion tablets and over 300 million capsules per annum. Targets the Saudi pharmaceutical market, the largest in the Middle East.
• Elixir Research and Development Services Pharmaceutical research and development services through a CGLP-compliant R&D center focused on pharmaceutical development for generics and new chemical entities, analytical research, novel drug delivery systems, non-infringing process development, complete impurity profiling, and GMP pilot plant capability for Exhibit Batches for regulatory submissions.
• Elixir Consulting Regulatory and Contract Manufacturing Services Regulatory services and contract manufacturing consulting, including dossier development, eCTD formatting, product registration, GMP inspection support, pharmacovigilance, and third-party manufacturing advisory across GCC, Africa, and EU markets, sold to pharmaceutical companies needing market entry support.
• Sinbad (Sildenafil) Product Launch Sildenafil product for erectile dysfunction launched by NPI in the UAE market in 2017.

Quantifiable outcome

• Registered in 30 European Union countries
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• SUN EnterprisescoreChannel Partner/ Reseller/ Distributor · 1 January 2020Local pharmaceutical distributor partnership in Rwanda established during OPEX 2020 (Omani Products Exhibition) held in Kigali, Rwanda. NPI signed agreement with SUN enterprises for distribution of pharmaceutical products in Rwandan market.
• Dar Al AttaminorStrategic or Co-development Partner · 1 January 2020Shifa initiative partnership for donating 2000 boxes of different medications to Muttrah, Oman community.
• KIMS Hospital, OmanminorStrategic or Co-development Partner · 1 January 2019Corporate Social Responsibility partnership under which NPI coordinated with KIMS Hospital to conduct medical camp providing free samples to needy patients.
• National Life & General Insurance Company (NLGIC)coreStrategic or Co-development Partner · 1 January 2018Partnership event to promote generic medicine. NLGIC CEO briefed on convenience of generic medicines for insurance clearance. NPI Corporate QA Head presented on Role of Generic Pharma Industry in Developing Healthcare.

Scale indicators7 records

Recent moves12 records

Expansion highlights7 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): UAE-based GCC-headquartered manufacturer of branded generics across multiple therapy areas with manufacturing in UAE and international distribution. Highly comparable to NPI in regional positioning, therapeutic breadth, and government-tender dependence.
• Eva Pharma: Egypt-based generic pharmaceutical manufacturer with strong presence across MENA and Africa, exporting branded generics. Comparable scale, therapeutic breadth, and emerging-market orientation to NPI.
• Neopharma: UAE-based branded-generic manufacturer with similar therapeutic breadth and GCC regulatory footprint (JAFZA manufacturing). Direct head-to-head competitor in UAE and broader Gulf tenders.
• Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): Saudi Arabia's flagship generic pharmaceutical manufacturer producing oral solids, syrups, and injectables with extensive local-government procurement relationships. Closest comparable peer in NPI's most important target market.
• Tabuk Pharmaceuticals Manufacturing Company: KSA-based generics manufacturer with broad portfolio across cardiovascular, anti-infective, CNS, and GI categories, exporting to MENA and Africa. Operates similar brand-generic GTM to NPI and competes head-to-head for GCC tenders.

Broad incumbents

• Cipla: Indian pharmaceutical major with leading branded-generic position across Africa, India, and emerging markets. Direct comparator for therapy-area portfolio breadth and respiratory/anti-infective generics where NPI has exposure.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generics and specialty pharma major with large manufacturing footprint across MENA and US. Much larger and more diversified than NPI but the dominant regional peer for branded-generic scale and EU/USFDA supply.
• Dr. Reddy's Laboratories: Large Indian generic manufacturer with deep emerging-market distribution including MENA and Africa. Competes with NPI in generic tenders while operating at materially larger scale.
• Aurobindo Pharma: Indian-headquartered global generics major with extensive GCC and African registrations and EUGMP/USFDA manufacturing. Sets aggressive pricing benchmarks in the same tender markets where NPI competes.

Regional players

• Pharma International (Jordan): Jordan-based generic manufacturer with strong MENA presence and EUGMP capability, similar in scale and business model to NPI. Serves comparable GCC, African, and CIS markets with branded generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/npioman
• LinkedInlinkedin.com/company/national-pharmaceutical-industries-company

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Pharmaceutical Industries Co.